Asset Details
Do you wish to reserve the book?
β‐Sitosterol as an Anti‐Tumour Active Component of Herba Sarcandrae Inhibits Colorectal Cancer Progression Through Up‐Regulation of TBX20
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
β‐Sitosterol as an Anti‐Tumour Active Component of Herba Sarcandrae Inhibits Colorectal Cancer Progression Through Up‐Regulation of TBX20
Do you wish to request the book?
β‐Sitosterol as an Anti‐Tumour Active Component of Herba Sarcandrae Inhibits Colorectal Cancer Progression Through Up‐Regulation of TBX20
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
β‐Sitosterol as an Anti‐Tumour Active Component of Herba Sarcandrae Inhibits Colorectal Cancer Progression Through Up‐Regulation of TBX20
2025
Overview
Colorectal cancer (CRC) is a common malignant tumor of the digestive tract with a high incidence rate. Herba Sarcandrae (HS) is an antipyretic and has been reported to have anti‐cancer effects. This study explored the impacts of β‐sitosterol on the sensitivity of CRC to 5‐fluorouracil (5‐FU) and oxaliplatin and the stability of TBX20 protein in CRC cells. There were 41 HS active ingredients and 265 corresponding potential targets, and 48 potential targets of HS were enriched in CRC. Then, 206 differentially expressed genes (DEGs) related to TBX20 overexpression were screened based on the TCGA database, some of which were associated with TMN stages of COAD patients. Epimedin C, rutin, and β‐sitosterol, which could be combined with TBX20, were screened and validated in CRC cells. Functionally, β‐sitosterol could suppress proliferation and induce apoptosis of CRC cells. β‐sitosterol could also enhance the sensitivity of CRC to 5‐FU and oxaliplatin. In xenograft models, both HS and β‐sitosterol treatments inhibited tumor growth and upregulated TBX20 protein expression, with β‐sitosterol demonstrating a stronger effect. Mechanistically, β‐sitosterol may stabilize TBX20 by inhibiting its ubiquitin‐mediated degradation. In conclusion, β‐sitosterol, as an anti‐tumor active component of HS, prevents CRC cell proliferation, and accelerates apoptosis by upregulating TBX20.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Animals
/ Cancer
/ Cell Proliferation - drug effects
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - genetics
/ Colorectal Neoplasms - metabolism
/ Colorectal Neoplasms - pathology
/ Disease
/ Female
/ Gene Expression Regulation, Neoplastic - drug effects
/ Genes
/ Humans
/ Male
/ Mice
/ Ontology
/ Original
/ Proteins
/ R&D
/ Rutin
/ Software
/ T-Box Domain Proteins - genetics
/ T-Box Domain Proteins - metabolism
/ TBX20
/ Traditional Chinese medicine
/ Tumors
/ Up-Regulation - drug effects
